Cantrell Drug Company amends FDA registration to include 503B compounding outsourcing facility

Cantrell Drug Company today announced amendment of its U.S. Food and Drug Administration (FDA) registration to include the new 503B “compounding outsourcing facility” designation established under the recently passed Drug Quality and Security Act so that it can continue to serve patients nationwide with sterile medications that meet the most exacting quality standards. …read more